MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.40 (55.50% upside)

Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$30.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/10/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2011($0.02)$0.08ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
DateHeadline
06/30/16 09:50 AMVanda Pharmaceuticals : Why Investors Love These Biotech's Stocks? - ImmunoGen, Immunomedics, Vanda Pharma, and Arrowhead Pharma
06/29/16 07:02 PMNew Broker Ratings For Vanda Pharmaceuticals Inc. (VNDA) - FTSE News
06/29/16 07:02 PMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Company Rating and Target Watch - Telanagana Press
06/28/16 06:19 AMHow Many Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)'s Analysts Are Bearish? - Press Telegraph
06/27/16 06:56 PMShare Update and Earnings Review for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Press Telegraph
06/27/16 06:19 AMVanda Pharmaceuticals Inc. (VNDA) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 06:28 AMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Yearly Accounts Payable At $15.767 Millions - RealistInvestor.com
06/25/16 10:47 AMVanda Pharmaceuticals Incorporated (NASDAQ:VNDA) Sellers Covered 13.83% of Their Shorts - Engelwood Daily
06/24/16 07:08 PMCovering the Bases on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Where is the Stock Going? - Press Telegraph
06/24/16 07:08 PMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 04:00 PMVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/23/16 07:56 PMEquity Research and Technical Review on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Press Telegraph
06/23/16 07:56 PMVanda Pharmaceuticals, Inc. (NasdaqGM:VNDA) Stock Momentum Hits Strength - CML News
06/20/16 04:19 PMVanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference - [at noodls] - WASHINGTON, June 20, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, will deliver a corporate presentation ...
06/19/16 06:19 AMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Accounts Payable Is $22.664 For The Quarter Ended 2016-03-31 - RealistInvestor.com
06/18/16 06:04 PMTrending Stock Analyst Review: Vanda Pharmaceuticals (NASDAQ:VNDA)
06/17/16 09:49 AMRecently Issued Stock Ratings For Vanda Pharmaceuticals Inc. (VNDA) - Fiscal Standard
06/16/16 04:01 PMVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 07:01 PMFDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia
06/15/16 01:35 PMFDA gives Vanda Pharmaceuticals three-year marketing exclusivity for Fanapt -
06/15/16 08:10 AMVanda Gets FDA Approval For Fanapt Marketing Exclusivity - Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) revealed that the U.S. Food and Drug Administration has granted three years of marketing exclusivity for the changes in respect of the supplemental New Drug Application (sNDA), which was ...Full story available on Benzinga.com
06/14/16 10:38 AMHow one investor is staying with Vanda -
06/10/16 07:33 PMBrokers Issue Average Price Target Of 17.25 On Vanda Pharmaceuticals Inc. (VNDA) - FTSE News
06/08/16 10:19 AMVANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Financial Condition Compared to S&P 500 - CML News
06/04/16 10:21 AMVenbio Select Advisor LLC Decreased Stake in Vanda Pharmaceuticals INC (NASDAQ:VNDA) by $3.25 Million as ... - CCH Daily News
06/03/16 10:14 AMShare Rating Focus on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - HNN
06/03/16 10:14 AMVanda Pharmaceuticals Inc. (VNDA) Jumps 5.68% on June 02 - Equities.com
06/03/16 06:25 AMVanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - WASHINGTON, June 3, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that it will deliver a corporate presentation at the Jefferies Healthcare Conference in New York ...
06/02/16 10:28 AMVanda Pharmaceuticals Inc. (VNDA) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Vanda Pharmaceuticals Inc. (VNDA) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Vanda Pharmaceuticals Inc. (VNDA). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/31/16 07:35 PMEarnings Expectations of the Stock: Vanda Pharmaceuticals (VNDA), XenoPort, (XNPT) - Beacon Chronicle - Beacon ChronicleEarnings Expectations of the Stock: Vanda Pharmaceuticals (VNDA), XenoPort, (XNPT)Beacon Chronicle... them, the Low Revenue estimate is $35.70 Million and High Revenue estimate is $36.40 Million. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) currently has High Price Target of $20.00. The Low and Mean Price Targets are $15.00 and $17.25 respectively.and more »
05/31/16 07:35 PMVanda Pharmaceuticals Inc. (VNDA) Rose To A 7-Month High After FDA Approval - RTT News - Small Cap Exclusive (press release)Vanda Pharmaceuticals Inc. (VNDA) Rose To A 7-Month High After FDA ApprovalRTT NewsVanda Pharmaceuticals Inc. (VNDA) announced after the close Thursday that it has received FDA approval for Fanapt for maintenance treatment for schizophrenia in adults. Vanda Pharmaceuticals gapped up Friday and climbed during the first hour of trade.Biotech Stocks Worth Chasing: Vanda Pharmaceuticals, Inc. (VNDA), Aratana Therapeutics, Inc. (PETX)ZergwatchVanda Pharmaceuticals Inc. (NASDAQ:VNDA): Price Target ProjectionsNews TribuneHow Analysts Rated Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Last Week?The PostCWRU Observer -Share Trading News -Small Cap Exclusive (press release)all 12 news articles »
05/31/16 03:18 PMIBB Rose 0.9% before the Long Weekend -
05/31/16 12:08 AMVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Daily Sentiment Score Of 0.28 - Investor Newswire - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Daily Sentiment Score Of 0.28Investor NewswireVanda Pharmaceuticals Inc. (NASDAQ:VNDA) has a daily sentiment score of 0.28. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web. The ...and more »
05/30/16 05:01 PMHC Sector update: Mast Therapeutics Inc (NYSEMKT:MSTX), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - share market updates (press release) - HC Sector update: Mast Therapeutics Inc (NYSEMKT:MSTX), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)share market updates (press release)Shares of Mast Therapeutics Inc (NYSEMKT:MSTX) ended Friday session in red amid volatile trading. The shares closed down -0.004 points or -1.15% at $0.336 with 2.02 million shares getting traded. Post opening the session at $0.34, the shares hit an ...
05/30/16 08:14 AMHot Stocks on Wall Street – VICL, RLYP, TTNP, FEIC, ULTA, JTPY, ROIAK, IXYS, VNDA, KURA - The company is -11.16 pct year-to-date, and -5.90 pct during the past four quarters. Vanda Pharmaceuticals Inc. (VNDA) traded at $10.17 + 0.68 (7.16 pct) on 342,755 total stock volume. The company is +9.24 pct year-to-date, and +2.05 pct during the past ...
05/27/16 10:25 PMVanda Pharmaceuticals Inc. (VNDA) Jumps 11.8% on May 27 - Equities.com - The Point ReviewVanda Pharmaceuticals Inc. (VNDA) Jumps 11.8% on May 27Equities.comVanda Pharmaceuticals Inc. (VNDA) was among the biggest gainers on the Russell 2000 for Friday May 27 as the stock popped 11.8% to $10.61, representing a gain of $1.12 per share. Some 1.98 million shares traded hands on 11,692 trades, compared ...Top Stories: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)The Point ReviewVanda Pharmaceuticals Inc. (VNDA) Latest Broker ViewsRisers & FallersVanda Pharmaceuticals Inc. (VNDA)'s Stock Jumps Following NDA ApprovalInsider Monkey (blog)Franklin Independent -Markets Daily -Wall Street Hints and Newsall 14 news articles »
05/27/16 05:17 PMTop Stories: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - The Point Review - The Point ReviewTop Stories: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)The Point ReviewShare of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded on 11.59 percent above secure line at 3:21PM EDT in order to take the company's stock at the price of $10.60. At the time of writing the stock exchanged hands 1.66 million shares versus average ...Vanda Pharmaceuticals Inc. (VNDA) Jumps 11.8% on May 27Equities.comVanda Pharmaceuticals Inc. (VNDA)'s Stock Jumps Following NDA ApprovalInsider Monkey (blog)Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Focus Stock Earnings and Rating ReviewFranklin IndependentWall Street Hints and News -The Post -Benchmark Monitorall 14 news articles »
05/27/16 03:43 PMUlta Salon, FEI and Vanda Pharma rise while Terex slumps -
05/27/16 11:01 AMVanda Pharmaceuticals Inc. (VNDA)’s Stock Jumps Following NDA Approval -
05/27/16 08:03 AMStocks Movements to Focus: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) , Laboratory Corporation of America ... - Street Updates - Stocks Movements to Focus: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) , Laboratory Corporation of America ...Street UpdatesOn 5/26/2016, shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell -2.37% in trading session and finally closed at $9.49. The company most recent volume stood at 809.42 thousand shares as compared to its average volume of 533.75 thousand ...and more »
05/26/16 10:14 PMStock Rating Review for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Wall Street Hints and News - Stock Rating Review for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/26/16 05:05 PMVanda Pharmaceuticals (VNDA) sNDA for Fanapt Approved by U.S. FDA for Schizophrenia - StreetInsider.com - Vanda Pharmaceuticals (VNDA) sNDA for Fanapt Approved by U.S. FDA for SchizophreniaStreetInsider.comVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced that the U.S. Food and Drug Administration (FDA) has approved Vanda's supplemental New Drug Application (sNDA) for Fanapt®, modifying and expanding the prescribing information (PI) to ...and more »
05/26/16 03:46 PMVANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/26/16 03:37 PMVanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults - [at noodls] - WASHINGTON, May 26, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Vanda's supplemental New Drug Application ...
05/26/16 08:15 AMTarget Check and Stock Performance Recap Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Wall Street Hints and News - Target Check and Stock Performance Recap Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Vanda Pharmaceuticals Inc.and more »
05/26/16 08:15 AMTraders Focused Stocks: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) , Agenus Inc. (NASDAQ:AGEN) - Street Updates - Traders Focused Stocks: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) , Agenus Inc. (NASDAQ:AGEN)Street UpdatesOn 5/25/2016, shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell -0.41% in trading session and finally closed at $9.72. The company most recent volume stood at 618.39 thousand shares as compared to its average volume of 527.38 thousand ...
05/25/16 10:02 PMInsiders Are Gradually Buying Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) - Wall Street Hints and News - Insiders Are Gradually Buying Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) have increased their position in the stock by 125.73% over the past 6 months. Insiders now own 2.20% of total outstanding shares. There are both legal and ...and more »
05/23/16 09:51 AMVanda Pharmaceuticals Inc. (VNDA) Broker Price Targets For The Coming Week - Share Trading News - Vanda Pharmaceuticals Inc. (VNDA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Vanda Pharmaceuticals Inc. (VNDA). The latest reports which are currently in issue on Monday 23rd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...and more »
05/20/16 05:00 PMAnalyst Rating Check on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - Wall Street Hints and News - Analyst Rating Check on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)Wall Street Hints and NewsCurrently, sell-side analysts have provided a consensus stock rating of 1 on shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Analysts that cover the company will usually offer Buy, Sell, or Hold recommendations based on in-depth research.and more »
05/19/16 10:12 PMInsiders Are Buying Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) - Wall Street Hints and News - Insiders Are Buying Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) have increased their position in the stock by 123.30%. Insiders now own 2.20% of total outstanding shares. There are both legal and illegal types of insider trading.and more »
About Vanda Pharmaceuticals

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VNDA
  • CUSIP: 92165910
Key Metrics:
  • Previous Close: $11.19
  • 50 Day Moving Average: $10.33
  • 200 Day Moving Average: $8.99
  • P/E Ratio: N/A
  • P/E Growth: -0.86
  • Market Cap: $482.88M
  • Current Quarter EPS Consensus Estimate: $-0.83 EPS
Additional Links:
Vanda Pharmaceuticals (NASDAQ:VNDA) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha